Sort   by:  
 Page size 
ProteomicsGlobal proteomics to study silica nanoparticle-induced cytotoxicity and its mechanisms in HepG2 cells
Silica nanoparticles (SiO2 NPs) are commonly used in medical and pharmaceutical fields. Research into the cytotoxicity and overall proteomic changes occurring during initial exposure to SiO2 NPs is limited. We investigated the mechanism of toxicity in human liver cells according to exposure time [0,...
ORGANISM(S): Homo sapiens (Human) 
2021-09-10 | PXD024206 | Pride
Silica nanoparticles  cytotoxicity  label-free quantification  proteomic analysis  mass spectrometry 
UnknownIn silico and in vitro insights into tyrosinase inhibitors with a 2-thioxooxazoline-4-one template.
Not available
S-EPMC7753086 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
UnknownGeneral and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7·5 million participants.
Not available
S-EPMC7616775 | biostudies-literature
UnknownEffects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
Sort   by:  
 Page size